Breakthrough COVID-19 in vaccinated patients with hematologic malignancies results from EPICOVIDEHA survey /
Limited data have been published on the epidemiology and outcomes of breakthrough COVID-19 in patients with hematological malignancy (HM) after anti-SARS-CoV-2 vaccination. Adult HM who received at least one dose of anti-SARS-CoV-2 vaccine and diagnosed with breakthrough COVID-19 between January 202...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2022
|
| Sorozat: | BLOOD
140 No. 26 |
| Tárgyszavak: | |
| doi: | 10.1182/blood.2022017257 |
| mtmt: | 33127891 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/25282 |
| LEADER | 03448nab a2200409 i 4500 | ||
|---|---|---|---|
| 001 | publ25282 | ||
| 005 | 20230103155905.0 | ||
| 008 | 221006s2022 hu o 0|| Angol d | ||
| 022 | |a 0006-4971 | ||
| 024 | 7 | |a 10.1182/blood.2022017257 |2 doi | |
| 024 | 7 | |a 33127891 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a Angol | ||
| 100 | 1 | |a Pagano Livio | |
| 245 | 1 | 0 | |a Breakthrough COVID-19 in vaccinated patients with hematologic malignancies |h [elektronikus dokumentum] : |b results from EPICOVIDEHA survey / |c Pagano Livio |
| 260 | |c 2022 | ||
| 300 | |a 2773-2787 | ||
| 490 | 0 | |a BLOOD |v 140 No. 26 | |
| 520 | 3 | |a Limited data have been published on the epidemiology and outcomes of breakthrough COVID-19 in patients with hematological malignancy (HM) after anti-SARS-CoV-2 vaccination. Adult HM who received at least one dose of anti-SARS-CoV-2 vaccine and diagnosed with breakthrough COVID-19 between January 2021 and March 2022 and registered in EPICOVIDEHA were included in this analysis. A total of 1548 cases were included, mainly with lymphoid malignancies (1181 cases, 76%). After viral genome sequencing in 753 cases (49%), Omicron variant was prevalent (517, 68.7%). Most of the patients received at least two vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received specific treatment for COVID-19. After 30-days follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with Omicron variant was of 7.9%, comparable to that reported for the other variants. The 30-day mortality rate was significantly lower than in the pre-vaccine era (31%). In the univariable analysis, older age (p<0.001), active HM (p<0.001), severe and critical COVID-19 (p=0.007 and p<0.001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (p<0.001). In the multivariable model, older age, active disease, critical COVID-19 and at least 2-3 comorbidities were correlated with a higher mortality, whereas the administration of monoclonal antibodies, alone (p<0.001) or combined with antivirals (p=0.009), was observed protective. While mortality is significantly lower than in the pre-vaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals. EPICOVIDEHA (www.clinicaltrials.gov; National Clinical Trials identifier NCT04733729) is an international open web-based registry for patients with HMs infected with SARS-CoV-2. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 2 | |a Salmanton-García Jon |e aut |
| 700 | 0 | 2 | |a Marchesi Francesco |e aut |
| 700 | 0 | 2 | |a Ola Blennow |e aut |
| 700 | 0 | 2 | |a Gomes da Silva Maria |e aut |
| 700 | 0 | 2 | |a Glenthøj Andreas |e aut |
| 700 | 0 | 2 | |a van Doesum Jaap A. |e aut |
| 700 | 0 | 2 | |a Bilgin Yavuz M. |e aut |
| 700 | 0 | 2 | |a Lopez-Garcia Alberto |e aut |
| 700 | 0 | 2 | |a Itri Federico |e aut |
| 700 | 0 | 2 | |a Nunes Rodrigues Raquel |e aut |
| 700 | 0 | 2 | |a Weinbergerová Barbora |e aut |
| 700 | 0 | 2 | |a Farina Francesca |e aut |
| 700 | 0 | 2 | |a Dragonetti Giulia |e aut |
| 700 | 0 | 2 | |a Piukovics Klára |e aut |
| 700 | 0 | 2 | |a et al. |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/25282/7/33127891.pdf |z Dokumentum-elérés |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/25282/1/Pagano2022.pdf |z Dokumentum-elérés |